Exception detected!

Key "LIST" does not exist as the array is empty.

500 Internal Server Error - Twig_Error_Runtime

Stack Trace

  1. in src/Interlinks/Bundle/AppBundle/Resources/views/asia-site/article-list.html.twig at line 87  -
    1.         </div><!--col-md-12-->
    2.         <div class="col-md-12">
    3.             <ul class="listingli nopadding">
    4.                 {% if response.articleList.LIST is not empty and response.articleList.LIST is not empty %}
    5.                     {% for articleDetail in response.articleList.LIST %}
    6.                         <li>
    7.                             <p class="news-heading listing nomargine">
  2. at Twig_Template ->getAttribute (array(), 'LIST', array())
    in app/cache/prod/twig/ab/abf8e9b60d87184de18b8b4ddb63bf571d0e08032c934e47d8cd5d1790194680.php at line 241  +
  3. at __TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601 ->block_col_md_8 (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5363  +
  4. at Twig_Template ->displayBlock ('col_md_8', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/twig/b3/b35be2e0ca7a5ef3f8bc9bb203b48f6eafc2a6778bad219b1734a5f6967d6aad.php at line 515  +
  5. at __TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b ->block_col_md_12 (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5363  +
  6. at Twig_Template ->displayBlock ('col_md_12', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/twig/b3/b35be2e0ca7a5ef3f8bc9bb203b48f6eafc2a6778bad219b1734a5f6967d6aad.php at line 486  +
  7. at __TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b ->block_content (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5363  +
  8. at Twig_Template ->displayBlock ('content', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/twig/b3/b35be2e0ca7a5ef3f8bc9bb203b48f6eafc2a6778bad219b1734a5f6967d6aad.php at line 269  +
  9. at __TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b ->block_body (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5363  +
  10. at Twig_Template ->displayBlock ('body', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/twig/4c/4c09d4962d123574fabd5a478ea4aa7e9066fddac94ea26c469c3c4ea834a64f.php at line 58  +
  11. at __TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d ->doDisplay (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5481  +
  12. at Twig_Template ->displayWithErrorHandling (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('html' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_html'), 'title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'javascript' => array(object(__TwigTemplate_5c1573aecb1fb9d5652b9d9a1de0f80baa495b100d4543a7b6c1fce16d439c3d), 'block_javascript'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5457  +
  13. at Twig_Template ->display (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/twig/b3/b35be2e0ca7a5ef3f8bc9bb203b48f6eafc2a6778bad219b1734a5f6967d6aad.php at line 45  +
  14. at __TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b ->doDisplay (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5481  +
  15. at Twig_Template ->displayWithErrorHandling (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('title' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_title'), 'header' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_header'), 'metaTag' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_metaTag'), 'stylesheet' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_stylesheet'), 'pageStyle' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_pageStyle'), 'body_attr' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body_attr'), 'angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'body' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_body'), 'bodyTopContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyTopContent'), 'navigation' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_navigation'), 'container_one_close' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_close'), 'content' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_content'), 'col_md_12' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_12'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'col_md_4' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_col_md_4'), 'container_one_end' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_container_one_end'), 'footer' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_footer'), 'bottomBodyContent' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bottomBodyContent'), 'bodyOutPopup' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOutPopup'), 'bodyOut' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyOut'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript'), 'bodyCommon' => array(object(__TwigTemplate_cbc13361f0a631723c74393bd4114b95e7962119b30c76c608d6c1a5163ba41b), 'block_bodyCommon')))
    in app/cache/prod/classes.php at line 5457  +
  16. at Twig_Template ->display (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript')))
    in app/cache/prod/twig/ab/abf8e9b60d87184de18b8b4ddb63bf571d0e08032c934e47d8cd5d1790194680.php at line 30  +
  17. at __TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601 ->doDisplay (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript')))
    in app/cache/prod/classes.php at line 5481  +
  18. at Twig_Template ->displayWithErrorHandling (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate')))))), 'assetic' => array('debug' => true, 'vars' => object(ValueContainer), 'use_controller' => false), 'app' => object(GlobalVariables)), array('angular' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_angular'), 'col_md_8' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_col_md_8'), 'pagesScript' => array(object(__TwigTemplate_52ab4d6b95a1fa78d8b4f7f26148e5f69b9d73e2b0eea009cb8966a04bf3f601), 'block_pagesScript')))
    in app/cache/prod/classes.php at line 5457  +
  19. at Twig_Template ->display (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))))))))
    in app/cache/prod/classes.php at line 5464  +
  20. at Twig_Template ->render (array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))))))))
    in vendor/symfony/symfony/src/Symfony/Bridge/Twig/TwigEngine.php at line 50  +
  21. at TwigEngine ->render ('InterlinksAppBundle:asia-site:article-list.html.twig', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))))))))
    in vendor/symfony/symfony/src/Symfony/Bundle/TwigBundle/TwigEngine.php at line 67  +
  22. at TwigEngine ->render ('InterlinksAppBundle:asia-site:article-list.html.twig', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))))))))
    in vendor/symfony/symfony/src/Symfony/Bundle/TwigBundle/Debug/TimedTwigEngine.php at line 50  +
  23. at TimedTwigEngine ->render ('InterlinksAppBundle:asia-site:article-list.html.twig', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))))))))
    in vendor/symfony/symfony/src/Symfony/Bundle/TwigBundle/TwigEngine.php at line 92  +
  24. at TwigEngine ->renderResponse ('InterlinksAppBundle:asia-site:article-list.html.twig', array('response' => array('sectionList' => array(array('sectionId' => '25', 'name' => 'Pharma', 'aliasName' => 'pharma', 'sequence' => '2', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '33', 'name' => 'Generics', 'aliasName' => 'generics', 'sequence' => '1', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '34', 'name' => 'Drug Discovery', 'aliasName' => 'drug-discovery', 'sequence' => '2', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '95', 'name' => 'CMC & Manufacturing', 'aliasName' => 'cmc-and-manufacturing', 'sequence' => '3', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '96', 'name' => 'Clinical Trials', 'aliasName' => 'clinical-trials', 'sequence' => '4', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'), array('sectionId' => '97', 'name' => 'New Drug Applications', 'aliasName' => 'new-drug-applications', 'sequence' => '5', 'parentSectionId' => '25', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '26', 'name' => 'BioTech', 'aliasName' => 'bio-tech', 'sequence' => '3', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '35', 'name' => 'Biologics', 'aliasName' => 'biologics', 'sequence' => '1', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '36', 'name' => 'Stem Cells', 'aliasName' => 'stem-cells', 'sequence' => '2', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '37', 'name' => 'Vaccines', 'aliasName' => 'vaccines', 'sequence' => '3', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'), array('sectionId' => '98', 'name' => 'Therapeutics', 'aliasName' => 'therapeutics', 'sequence' => '4', 'parentSectionId' => '26', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '27', 'name' => 'MedTech', 'aliasName' => 'med-tech', 'sequence' => '4', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '104', 'name' => 'Medical Devices', 'aliasName' => 'medical-devices', 'sequence' => '2', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'), array('sectionId' => '105', 'name' => 'Medical Diagnostic', 'aliasName' => 'medical-diagnostic', 'sequence' => '3', 'parentSectionId' => '27', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '28', 'name' => 'BioServices', 'aliasName' => 'bio-services', 'sequence' => '5', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '38', 'name' => 'Contract Research', 'aliasName' => 'contract-research', 'sequence' => '1', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '39', 'name' => 'Clinical Research', 'aliasName' => 'clinical-research', 'sequence' => '2', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '40', 'name' => 'Contract Manufacturing', 'aliasName' => 'contract-manufacturing', 'sequence' => '3', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '99', 'name' => 'Pre Clinical Development', 'aliasName' => 'pre-clinical-development', 'sequence' => '4', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'), array('sectionId' => '100', 'name' => 'Clinical Trial Phase', 'aliasName' => 'clinical-trial-phase', 'sequence' => '5', 'parentSectionId' => '28', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '30', 'name' => 'Healthcare', 'aliasName' => 'healthcare', 'sequence' => '7', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '46', 'name' => 'Digital Health', 'aliasName' => 'digital-health', 'sequence' => '1', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '91', 'name' => 'COVID19', 'aliasName' => 'covid19', 'sequence' => '7', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'), array('sectionId' => '120', 'name' => 'Artificial Intelligence', 'aliasName' => 'artificial-intelligence', 'sequence' => '8', 'parentSectionId' => '30', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '106', 'name' => 'Bio LAB', 'aliasName' => 'bio-lab', 'sequence' => '8', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '107', 'name' => 'Lab Products', 'aliasName' => 'lab-product', 'sequence' => '1', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '108', 'name' => 'Lab Safety', 'aliasName' => 'lab-safety', 'sequence' => '2', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '109', 'name' => 'Lab Management', 'aliasName' => 'lab-management', 'sequence' => '3', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'), array('sectionId' => '110', 'name' => 'Lab Design', 'aliasName' => 'lab-design', 'sequence' => '4', 'parentSectionId' => '106', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '121', 'name' => 'HER Health', 'aliasName' => 'her-health', 'sequence' => '10', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '122', 'name' => 'Cell & Gene', 'aliasName' => 'cell-and-gene', 'sequence' => '11', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array()), array('sectionId' => '29', 'name' => 'Specials', 'aliasName' => 'specials', 'sequence' => '12', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '114', 'name' => 'Bio interaction', 'aliasName' => 'bio-interaction', 'sequence' => '0', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '88', 'name' => 'Premium Article', 'aliasName' => 'premium-article', 'sequence' => '1', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '44', 'name' => 'Biopreneurs', 'aliasName' => 'biopreneurs', 'sequence' => '2', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '41', 'name' => 'Industry Insights', 'aliasName' => 'industry-insights', 'sequence' => '3', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '102', 'name' => 'Bio Money', 'aliasName' => 'bio-money', 'sequence' => '9', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '103', 'name' => 'Bio Informatics', 'aliasName' => 'bio-informatics', 'sequence' => '10', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '111', 'name' => 'Bio Jobs', 'aliasName' => 'bio-jobs', 'sequence' => '11', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '112', 'name' => 'Infomercial', 'aliasName' => 'infomercial', 'sequence' => '12', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '113', 'name' => 'Partner Content', 'aliasName' => 'partner-content', 'sequence' => '13', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'), array('sectionId' => '115', 'name' => 'BioSpectrum Asia Awards 2022', 'aliasName' => 'bsa-awards-2022', 'sequence' => '14', 'parentSectionId' => '29', 'siteId' => '1', 'status' => '1'))), array('sectionId' => '32', 'name' => 'Country', 'aliasName' => 'country', 'sequence' => '13', 'parentSectionId' => '0', 'siteId' => '1', 'status' => '1', 'childSection' => array(array('sectionId' => '47', 'name' => 'Australia', 'aliasName' => 'australia', 'sequence' => '1', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-au'), array('sectionId' => '48', 'name' => 'China', 'aliasName' => 'china', 'sequence' => '2', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-cn'), array('sectionId' => '49', 'name' => 'India', 'aliasName' => 'india', 'sequence' => '3', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-in'), array('sectionId' => '50', 'name' => 'Japan', 'aliasName' => 'japan', 'sequence' => '4', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-jp'), array('sectionId' => '51', 'name' => 'Korea', 'aliasName' => 'korea', 'sequence' => '5', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-kr'), array('sectionId' => '52', 'name' => 'Malaysia', 'aliasName' => 'malaysia', 'sequence' => '6', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-my'), array('sectionId' => '53', 'name' => 'New Zealand', 'aliasName' => 'new-zealand', 'sequence' => '7', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-nz'), array('sectionId' => '54', 'name' => 'Singapore', 'aliasName' => 'singapore', 'sequence' => '8', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-sg'), array('sectionId' => '55', 'name' => 'Taiwan', 'aliasName' => 'taiwan', 'sequence' => '9', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-tw'), array('sectionId' => '56', 'name' => 'Thailand', 'aliasName' => 'thailand', 'sequence' => '10', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1', 'flag' => 'flag-th'), array('sectionId' => '93', 'name' => 'Indonesia', 'aliasName' => 'indonesia', 'sequence' => '11', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '94', 'name' => 'Vietnam', 'aliasName' => 'vietnam', 'sequence' => '12', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '89', 'name' => 'North America', 'aliasName' => 'north-america', 'sequence' => '13', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '83', 'name' => 'World', 'aliasName' => 'world', 'sequence' => '14', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '86', 'name' => 'Middle East countries', 'aliasName' => 'middle-east-countries', 'sequence' => '15', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '90', 'name' => 'Europe', 'aliasName' => 'europe', 'sequence' => '16', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1'), array('sectionId' => '87', 'name' => 'SAARC', 'aliasName' => 'saarc', 'sequence' => '17', 'parentSectionId' => '32', 'siteId' => '1', 'status' => '1')))), 'footerTopLeftDetail' => array('articleId' => '59', 'articleTitle' => 'Footer Top Left', 'seoTitle' => null, 'seoSummary' => null, 'seoGenerator' => null, 'seoAuthor' => null, 'seoAppName' => null, 'subheading' => 'Subscribe to BioSpectrum Asia', 'titleText' => 'Subscribe Now!', 'titleUrl' => 'https://www.biospectrumasia.com/subscription/Subscription.php', 'introDescription' => '', 'page1' => '', 'page2' => null, 'page3' => null, 'page4' => null, 'page5' => null, 'guestAuthor' => null, 'remark' => null, 'primaryMedium' => 'Text', 'flashNews' => '0', 'specialFeature' => '0', 'city' => null, 'imagePath' => 'uploads/static/bsa_march_2024_issue_cover_page_jpg_1_-59.jpg', 'imageTitle' => '', 'sequence' => '59', 'publishDateTime' => null, 'expiryDateTime' => null, 'displayDate' => null, 'editingNotes' => '', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'status' => 'Published', 'contentTypeId' => '13', 'siteId' => '1', 'sourceId' => '1', 'userId' => '4', 'lastUpdatedByUserId' => '28', 'articleType' => 'Static', 'language' => null, 'blogType' => null, 'pageSlug' => 'footer-top-left', 'magazineIssue' => null, 'pullquote' => null, 'restrictionType' => null, 'seoKeyword' => null, 'articleReadCount' => '0'), 'subsectionAlias' => 'specials', 'subsection' => 'Specials', 'section' => '', 'sectionId' => '', 'editorPickArticleList' => array(array('articleId' => '23839', 'sourceId' => '1', 'contentTypeId' => '3', 'articleTitle' => 'Engendering Inclusivity & Diversity in Life Sciences', 'imagePath' => 'uploads/articles/her-23839.png', 'imageTitle' => '', 'pageSlug' => 'engendering-inclusivity-diversity-in-life-sciences', 'contentType' => 'Influencers', 'contentTypeSlug' => 'influencers', 'sectionId' => '121'), array('articleId' => '23845', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?', 'imagePath' => 'uploads/articles/tb-23845.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'can-shorter-regimens-eliminate-drug-resistant-tuberculosis', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '25'), array('articleId' => '23846', 'sourceId' => '1', 'contentTypeId' => '1', 'articleTitle' => 'Why Singapore is Deep Tech Innovation Frontrunner', 'imagePath' => 'uploads/articles/ss-23846.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'why-singapore-is-deep-tech-innovation-frontrunner', 'contentType' => 'Analysis', 'contentTypeSlug' => 'analysis', 'sectionId' => '26'), array('articleId' => '23847', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '"One example of success is the development of a potential new paediatric treatment for schistosomiasis" ', 'imagePath' => 'uploads/articles/ghit-23847.png', 'imageTitle' => '', 'pageSlug' => 'one-example-of-success-is-the-development-of-a-potential-new-paediatric-treatment-for-schistosomiasis-', 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '98')), 'mostReadArticleList' => array(array('articleId' => '23770', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement', 'imagePath' => 'uploads/articles/lab-23770.jpeg', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'biocytogen-pharma-beijing-and-gilead-enter-into-multi-target-antibody-collaboration-agreement', 'page1' => '<p style="text-align: justify;">Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with&nbsp;American biopharmaceutical company Gilead Sciences, Inc.</p> <p style="text-align: justify;">The agreement provides Gilead access to Biocytogen&rsquo;s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.</p> <p style="text-align: justify;">Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead&rsquo;s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.</p> <p style="text-align: justify;">Biocytogen&rsquo;s antibody library was generated using a series of proprietary RenMice&nbsp;platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMab&nbsp;mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties.</p>', 'sequence' => '1', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '26'), array('articleId' => '23769', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Researchers in Asia develop tool to help patients after kidney transplantation', 'imagePath' => 'uploads/articles/kidney-23769.png', 'imageTitle' => 'image credit- shutterstock', 'pageSlug' => 'researchers-in-asia-develop-tool-to-help-patients-after-kidney-transplantation', 'page1' => '<p style="font-weight: 400; text-align: justify;">A global team of researchers&nbsp;from Australia, US, UK, France, Korea, and George Institute India have collaborated to develop a tool (SONG &ndash; LP) to assess life participation, or the ability to engage in daily life activities of people who have had kidney transplants.</p> <p style="font-weight: 400; text-align: justify;">In a global consensus process involving more than 1100 patients, caregivers, and health professionals from over 70 countries, life participation was established as a critically important outcome for kidney transplant recipients. The ability to consistently measure this outcome is valuable to inform routine care, clinical audit, and research.</p> <p style="font-weight: 400; text-align: justify;">Recognising the importance of life participation among kidney transplant patients, researchers collaborated in a global initiative involving 249 adult kidney transplant recipients from 20 countries to develop a tool to measure this important parameter&nbsp;for transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">This was done through a consensus workshop with inputs from all relevant stakeholder groups (patients, caregivers, and health professionals) on developing content for the SONG-LP (Standardised Outcomes in Nephrology life participation), a core patient-reported outcome measure for life participation in kidney transplant recipients.</p> <p style="font-weight: 400; text-align: justify;">The tool is in the form of a questionnaire called SONG-LP for adults who had kidney transplants. The questionnaire asks about four aspects of their life: leisure, family, work, and social activities. The participants answer each question on a scale from 0 (never) to 4 (always). The total score is the average of all four answers.</p> <p style="font-weight: 400; text-align: justify;">The SONG-LP instrument assesses the well-being of individuals with kidney transplants. It evaluates their capability to actively participate in daily life activities, covering various aspects such as leisure, family, work, and social interactions.</p> <p style="font-weight: 400; text-align: justify;">The team aims to conduct future research to include a more diverse group of kidney transplant recipients, ranging from those facing health issues to those in good health. This will help determine whether the observed high levels of life participation are consistent&nbsp;across the entire kidney transplant recipient community or if they apply more to specific.</p>', 'sequence' => '2', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '101'), array('articleId' => '23767', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'Japan's Nanophoton strengthens Bruker’s portfolio of molecular microscopy research solutions', 'imagePath' => 'uploads/articles/micro-23767.png', 'imageTitle' => '', 'pageSlug' => 'japans-nanophoton-strengthens-brukers-portfolio-of-molecular-microscopy-research-solutions', 'page1' => '<p style="text-align: justify;">US-based&nbsp;Bruker Corporation&nbsp;has announced the acquisition of&nbsp;Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced&nbsp;Raman microscopes, serving academic and industrial research customers, primarily in Japan.</p> <p style="text-align: justify;">This acquisition fills a gap in Bruker&rsquo;s molecular microscopy portfolio, and Bruker intends to offer fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.</p> <p style="text-align: justify;">Nanophoton augments the molecular microscopy portfolio of the Bruker Optics division with a broad range of state-of-the-art&nbsp;Raman microscopy systems, which offer exceptional speed, sensitivity and spatial resolution, combined with user-friendly workflows designed for outstanding user experience.</p> <p style="text-align: justify;">The applications include inspecting advanced semiconductor and nanomaterials, batteries, organic and liquid-crystal displays, nanocarbon materials, identifying organic components, mapping the distribution of active pharmaceutical ingredients and excipients in tablets, and clinical research on disease patterns in tissues.</p>', 'sequence' => '3', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '50'), array('articleId' => '23765', 'sourceId' => '1', 'contentTypeId' => '4', 'articleTitle' => 'China Medical University Hospital in Taiwan upgrades smart healthcare with Gen AI', 'imagePath' => 'uploads/articles/54-23765.png', 'imageTitle' => 'Image credit: prnewswire', 'pageSlug' => 'china-medical-university-hospital-in-taiwan-upgrades-smart-healthcare-with-gen-ai', 'page1' => '<p style="text-align: justify;">China Medical University Hospital (CMUH) in <span class="xn-location">Taiwan</span> announced its collaboration with Google Cloud in <span class="xn-chron">mid-December 2023</span>. Using&nbsp;Google Cloud's generative AI technology, including&nbsp;MedLM, which is&nbsp;a large language model built on Med-PaLM 2, CMUH has developed a comprehensive artificial intelligence (AI)-assisted Physician system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc.&nbsp;</p> <p style="text-align: justify;">The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including 'Customised Cancer Treatment Guidelines' and 'Cancer Therapy Q&amp;As', aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalised treatment-related information to patients, and providing responses to patient health education inquiries.</p> <p style="text-align: justify;">CMUH is one of the first university hospitals&nbsp;in <span class="xn-location">Asia</span> to test&nbsp;MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in <span class="xn-location">Taiwan</span>. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best healthcare AI models for the Chinese-speaking market in <span class="xn-location">Asia</span>.&nbsp;</p> <p style="text-align: justify;">In addition, in terms of new drug development, CMUH is leveraging Google's unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilising these resources can reduce the computation time for related programmes by over tenfold.</p>', 'sequence' => '4', 'guestAuthor' => '', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'News', 'contentTypeSlug' => 'news', 'sectionId' => '30')), 'specialFeaturesArticleList' => array(array('articleId' => '23841', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => 'How pharma is finally researching issues that primarily affect women', 'imagePath' => 'uploads/articles/cara-23841.png', 'imageTitle' => '', 'pageSlug' => 'how-pharma-is-finally-researching-issues-that-primarily-affect-women', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Until recently, clinical trials largely focused on catering to men's and men&rsquo;s health issues; focusing less on conditions that affected women alone, or even primarily. This dynamic has resulted in a lack of treatments and knowledge about women-specific diseases, as well as clinical trial practices that aren&rsquo;t typically tailored to women&rsquo;s unique needs.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">The good news is that we&rsquo;re seeing pharma shifting focus towards issues that affect this half of the population. With more women-focused trials on the horizon, female participation will now directly contribute to therapies for diseases that exclusively or disproportionately affect them (think: breast cancer, menopause, thyroid disease, to name a few).</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">This creates new urgency for sponsors to address challenges that keep women from completing the full duration of studies, to ensure these studies can bring meaningful treatments to the public with minimal delays.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Be considerate of scheduling</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Many women are still the chief caregivers in their families, responsible for their kids, maintaining their homes, and sometimes even caring for their parents. Between these roles, as well as obligations like work, it can be almost impossible to find a moment for themselves, not to mention, take part in a clinical trial. If a woman has a standing appointment to check in for a trial, but her child is sick, she may be unable to participate that day. Sponsors need to be prepared to address these nuanced needs and coach sites on ways to be flexible.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Knowing that childcare can be a limiting factor, for instance, we provided activities to keep kids occupied in the waiting room during one trial we worked on. Even if the kids didn&rsquo;t play the games, their mothers felt more comfortable knowing their children could attend with them and had something to do while waiting. Perhaps most importantly, they appreciated that sites were considering their families as part of the process.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Women value being heard</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Healthcare is personal and intimate, and when receiving care, people want to be listened to. A core tenant of trial recruitment is taking this into account. In addition to connecting participants with skilled nurses who act as one-on-one guides throughout the process, one approach we&rsquo;ve seen a high degree of success with is conducting participant surveys. Through these surveys, we can understand their experiences to better accommodate trials going forward.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For some women, showing appreciation for their participation and acknowledging the obstacles they had to navigate to join goes a long way. For others, learning about their burdens&ndash;and connecting with them around their challenges&ndash;is enough to keep them engaged and involved.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">These small acts are not only insightful for researchers, they make women feel heard, which can directly influence their willingness to move forward with research.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">As more studies that focus on women or include them as prioritised populations emerge, the industry needs to be prepared to listen and adapt to their unique journey. This will require going beyond focusing on how therapies impact them, and influence the very structure of clinical trials and trial sites.&nbsp;</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><strong>Cara Brant, CEO, Clinical Trial Media&nbsp;</strong></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em></em>Read the <a href="../../../opinion/121/23842/evolution-of-womens-representation-in-clinical-trials.html" target="_blank">next</a> part....</p>', 'sequence' => '1', 'guestAuthor' => 'Cara Brant, CEO, Clinical Trial Media ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121'), array('articleId' => '23843', 'sourceId' => '1', 'contentTypeId' => '5', 'articleTitle' => '3 Practical Ways to Encourage Women’s Clinical Trial Participation', 'imagePath' => 'uploads/articles/aly-23843.png', 'imageTitle' => '', 'pageSlug' => '3-practical-ways-to-encourage-womens-clinical-trial-participation', 'page1' => '<p style="text-align: justify;"><span style="font-weight: 400;">Clinical trial recruitment and retention remain pressing issues industry-wide even as the research landscape undergoes ongoing changes to become more accessible for patients &mdash; from on-site to at home. Women in particular face a unique set of challenges to participation, but the good news is that feasible solutions are available. All they require is a commitment to action. Here are three easy yet too often overlooked ways to make clinical trial participation better for female participants.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><strong>Create an atmosphere of trust</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">The unfortunate truth is that women face an uphill battle in having their medical concerns taken seriously by medical professionals. They are used to having their pain dismissed, their discomfort overlooked, and their conditions misdiagnosed. Ensuring that site staff and primary investigators are aware of this implicit bias trend and actively working to mitigate it is essential to creating an atmosphere of trust so women can feel comfortable participating in the clinical trial.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Offer childcare options</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">Not all women who sign up for clinical trials have young children to care for, of course, but many do. Even elderly female patients in the study may be serving as a primary caregiver. Ensure that they are not barred from trial participation if they can&rsquo;t find child care. Build on-site child care options into any study involving women, and/or offer decentralised trial options when possible so they don&rsquo;t need to disrupt their typical caretaker schedules to participate.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">&nbsp;</span></p> <p style="text-align: justify;"><strong>Staff-supported study travel</strong></p> <p style="text-align: justify;"><span style="font-weight: 400;">For study participants of all genders who need to travel to participate in the research, the question of whether they will need to give up their jobs to participate is a very real one. So naturally, financial and travel support for study participants is essential. However, there is another aspect of study travel support that is frequently overlooked: personal support.</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">For patients suffering from chronic debilitating illness or disease, travel can be emotionally, mentally, and physically overwhelming. Not everyone has someone from their community with the time, resources, and ability to travel with them to study and support them in simply getting from point A to point B. A study-assigned travel companion who can help the patient get to and from the airport, the train station, the bus, or even just the parking lot can make a world of difference. Women in particular may feel vulnerable traveling alone. Providing staff-supported study travel helps them participate with more confidence and ease.&nbsp;</span></p> <p style="text-align: justify;"><span style="font-weight: 400;">Being proactive about meeting the female patients&rsquo; needs from day one of the studies &mdash; and ensuring that potential participants understand the full scope of such efforts &mdash; will make recruitment and retention of women in the study much easier and more sustainable. At the end of the day, we must always remember that people are at the core of everything we do. If we want faster, more efficient, cost-effective research, we need to recruit and retain the right patients for every study. These steps help make that possible.</span></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"><strong>Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All&nbsp;</strong></span></em></p> <p style="text-align: justify;">&nbsp;</p> <p style="text-align: justify;"><em><span style="font-weight: 400;"></span></em><span style="font-weight: 400;">Read the <a href="../../../opinion/121/23844/surmounting-gender-based-obstacles-in-clinical-trials.html" target="_blank">next</a> part....</span></p>', 'sequence' => '2', 'guestAuthor' => 'Alyssa Greiner, Program Lead and Spokesperson, Clinical Trials For All ', 'displayDate' => object(DateTime), 'publishDateTime' => object(DateTime), 'contentType' => 'Opinion', 'contentTypeSlug' => 'opinion', 'sectionId' => '121')), 'pollQuestionDetails' => array('pollQuestionId' => '95', 'title' => 'Is APAC region engendering inclusivity & diversity in life sciences?', 'slug' => 'is-apac-region-engendering-inclusivity-diversity-in-life-sciences', 'question' => '', 'status' => '1', 'deleteStatus' => '0', 'lastUpdationDate' => object(DateTime), 'creationDate' => object(DateTime), 'userId' => '11', 'siteId' => '1', 'pollOptionList' => array(array('pollOptionId' => '242', 'option' => 'Yes', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '243', 'option' => 'No', 'clicks' => '0', 'pollQuestionId' => '95'), array('pollOptionId' => '244', 'option' => 'May be', 'clicks' => '1', 'pollQuestionId' => '95'))), 'articleList' => array(), 'researchReportsList' => array(array(array('id' => '1', 'reportName' => 'Asia-Pacific Biologics CMO Facilities', 'author' => 'IMAPAC Pte Ltd', 'description' => ' Access in-depth research and analysis of Biologics Contract Manufacturers operating in key Asian markets - China, Taiwan, Korea, Japan, Southeast Asia, India and Australia. Expansion plans of over 50 CMOs in the APAC region along with insights such as current Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution,Financial Performance, Technologies Housed are available in the Asia-Pacific Biologics CMO Report.', 'image' => 'cms-images/CMO-Facilities.png', 'isActive' => '1', 'sequence' => '1', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '1', 'researchReportsId' => '1', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '5998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '2', 'researchReportsId' => '1', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '8898.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '3', 'researchReportsId' => '1', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))), array('id' => '2', 'reportName' => 'APAC Bioprocessing Facilities 2020', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Asia-Pacific Bioprocessing Facilities 2020 covers comprehensive information on parameters such as facility size, capacity, production technologies, types of biologics manufactured and much more!. It provides readers a closer look into the facilities of Chugai, Hanmi,, Daiichi Sankyo, Biocon (India & SEA), Beigene, Amgen (Singapore), GSK (Singapore) and more!', 'image' => 'cms-images/Bioprocessing-Facilities.png', 'isActive' => '1', 'sequence' => '2', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '4', 'researchReportsId' => '2', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7998.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '5', 'researchReportsId' => '2', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '6', 'researchReportsId' => '2', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '11998.00', 'package' => 'Corporate'))), array('id' => '3', 'reportName' => 'Global Coronavirus Vaccines Pipeline', 'author' => 'IMAPAC Pte Ltd', 'description' => 'Featuring 115 vaccine, 20 stem cell therapies and 22 antibody candidates, IMAPAC brings to you the Coronavirus Vaccine & Biologics Candidates – A Global Analysis report which brings together over 200 organizations working on a panacea for the COVID-19 pandemic. It comprises exclusive interviews with industry experts from Novavax, International Vaccine Institute, EpiVax and more, industry surveys and comprehensive secondary research. For more information, send us a request for the sample insights.', 'image' => 'cms-images/Coronavirus-Vaccine-Pipeline.png', 'isActive' => '1', 'sequence' => '3', 'publishDate' => '05-August-2020', 'createdAt' => '2020-08-05 13:49:49', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '7', 'researchReportsId' => '3', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '1499.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '8', 'researchReportsId' => '3', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '2499.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '9', 'researchReportsId' => '3', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '3299.00', 'package' => 'Corporate')))), array(array('id' => '4', 'reportName' => 'APAC Cell Therapy Bioprocessing 2020', 'author' => '', 'description' => 'The APAC Cell Therapy Bioprocessing 2020 report covers 62 Cell and Gene therapy facilities including CMOs and Biopharma in the APAC region including countries such as China, Japan, Korea, Taiwan, SEA, India and Australia. Some of the parameters covered in this report are: Revenue generated by the company for cell and gene therapy from 2017-2019, technologies used, production capacity, scale of production, services offered by the CMOs, future expansion plans and more! For more information, send us a request for the sample insights.', 'image' => 'cms-images/Cell-Therapy-Bioprocessing.png', 'isActive' => '1', 'sequence' => '4', 'publishDate' => '26-August-2020', 'createdAt' => '2020-08-26 16:27:17', 'researchReportsPackagesList' => array(array('researchReportsPackagesId' => '10', 'researchReportsId' => '4', 'packageId' => '1', 'amtExt' => 'SGD', 'amount' => '7198.00', 'package' => 'Single - User'), array('researchReportsPackagesId' => '11', 'researchReportsId' => '4', 'packageId' => '2', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Multi - User'), array('researchReportsPackagesId' => '13', 'researchReportsId' => '4', 'packageId' => '3', 'amtExt' => 'SGD', 'amount' => '9998.00', 'package' => 'Corporate'))))))))
    in vendor/sensio/framework-extra-bundle/EventListener/TemplateListener.php at line 117  +
  25. at TemplateListener ->onKernelView (object(GetResponseForControllerResultEvent), 'kernel.view', object(TraceableEventDispatcher))
  26. at call_user_func (array(object(TemplateListener), 'onKernelView'), object(GetResponseForControllerResultEvent), 'kernel.view', object(TraceableEventDispatcher))
    in vendor/symfony/symfony/src/Symfony/Component/EventDispatcher/Debug/WrappedListener.php at line 61  +
  27. at WrappedListener ->__invoke (object(GetResponseForControllerResultEvent), 'kernel.view', object(ContainerAwareEventDispatcher))
  28. at call_user_func (object(WrappedListener), object(GetResponseForControllerResultEvent), 'kernel.view', object(ContainerAwareEventDispatcher))
    in app/cache/prod/classes.php at line 2223  +
  29. at EventDispatcher ->doDispatch (array(object(WrappedListener)), 'kernel.view', object(GetResponseForControllerResultEvent))
    in app/cache/prod/classes.php at line 2156  +
  30. at EventDispatcher ->dispatch ('kernel.view', object(GetResponseForControllerResultEvent))
    in app/cache/prod/classes.php at line 2317  +
  31. at ContainerAwareEventDispatcher ->dispatch ('kernel.view', object(GetResponseForControllerResultEvent))
    in vendor/symfony/symfony/src/Symfony/Component/EventDispatcher/Debug/TraceableEventDispatcher.php at line 124  +
  32. at TraceableEventDispatcher ->dispatch ('kernel.view', object(GetResponseForControllerResultEvent))
    in app/bootstrap.php.cache at line 3057  +
  33. at HttpKernel ->handleRaw (object(Request), '1')
    in app/bootstrap.php.cache at line 3016  +
  34. at HttpKernel ->handle (object(Request), '1', true)
    in app/bootstrap.php.cache at line 3165  +
  35. at ContainerAwareHttpKernel ->handle (object(Request), '1', true)
    in app/bootstrap.php.cache at line 2406  +
  36. at Kernel ->handle (object(Request))
    in index.php at line 31  +

Logs  -

Stack Trace (Plain Text)  +